The pharma market has clearly grown to include manufacturers from a number of emerging markets and this trend is only expected to continue as referenced in the recent IMS Health report.
Dateline - Jordan. The Hikma pharmaceutical group reported (FT.com)profits were up 48% on sales increases of 12.5% (constant currency) - driven by sales growth in the generic segment in the US market. In fact generics sales were up 172% in the US and 28% WW. These represent more than 1/5 of company total revenues now and GM's doubled. Said Darwazeh, CEO, indicates the company has benefited from increased FDA scrutiny on low costs suppliers - who were "cutting corners" on quality. Hikma is confident that no one can beat it on price and meet regulatory quality standards.
Dateline - Taiwan. ScinoPharm, the CMO, reported strong sales of its anticancer APIs in Europe and Asia. Revenues and profits were both up 20% iin 2009. The firm believes its focus on high value cancer areas with sustain its growth in 2010 and beyond. ScinoPharm will introduce several new compounds this year used in treatment of breast, prostate and ovarian cancer. ScinoPharm also reportedly has 7 new biosimilars in its pipeline including cancer MAbs. Construction of its new contract manufacturing facility in Changshu, China is due to be completed in 2011. (See Outsourcing Pharma.com)
Posted by Bruce Lehr March 25th 2010.
Comments